Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment

Vemurafenib, a selective RAF inhibitor, extends survival among patients with BRAF V600E–mutant melanoma. Vemurafenib inhibits ERK signaling in BRAF V600E–mutant cells but activates ERK signaling in BRAF wild-type cells. This paradoxical activation of ERK signaling is the mechanistic basis for the de...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Callahan, Margaret K., Rampal, Raajit, Harding, James J., Klimek, Virginia M., Chung, Young Rock, Merghoub, Taha, Wolchok, Jedd D., Solit, David B., Rosen, Neal, Abdel-Wahab, Omar, Levine, Ross L., Chapman, Paul B.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2012
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3627494/
https://ncbi.nlm.nih.gov/pubmed/23134356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1208958
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन